Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21‐month analysis in Australian routine clinical practice ( <scp>SUSTAIN</scp> study)-Reference-Cited by-同舟云学术

Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21‐month analysis in Australian routine clinical practice ( SUSTAIN study)

Published:2022-07-09 Issue:3 Volume:63 Page:303-311
ISSN:0004-8380
Container-title:Australasian Journal of Dermatology
language:en
Short-container-title:Aust J Dermatology

Author:

Foley Peter¹²^ORCID,Manuelpillai Nick¹^ORCID,Dolianitis Con²³,Cains Geoffrey D.⁴,Mate Eric⁵,Tronnberg Rebecca⁵,Baker Christopher¹²

Affiliation:

1. Skin Health Institute Carlton Victoria Australia

2. The University of Melbourne, St Vincent's Hospital Melbourne Fitzroy Victoria Australia

3. Royal Melbourne Hospital Parkville Victoria Australia

4. Liverpool Hospital Sydney New South Wales Australia

5. Novartis Pharmaceuticals, Australia Pty Limited Macquarie Park New South Wales Australia

Funder

University of Melbourne

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajd.13895

Reference19 articles.

1. Putting together the psoriasis puzzle: an update on developing targeted therapies

2. Drug survival, discontinuation rates, and safety profile of secukinumab in real‐world patients: a 152‐week, multicenter, retrospective study

3. A Canadian Self-Administered Online Survey to Evaluate the Impact of Moderate-to-Severe Psoriasis among Patients

4. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Survival, Safety, and Effectiveness of Secukinumab for up to 5 Years in Patients with Psoriasis and Psoriatic Arthritis: A Long-Term Real-Life Experience;Journal of Personalized Medicine;2024-07-03

2. Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective Study;Journal of Clinical Medicine;2024-06-30

3. Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis;Drugs;2024-04-17

4. Long-term efficacy, safety, and drug survival of secukinumab in patients with psoriasis in Turkey: a retrospective analysis of real-world experience;Advances in Dermatology and Allergology;2024

5. Real-world safety and effectiveness of secukinumab in adult patients with moderate to severe plaque psoriasis: results from postmarketing surveillance in Korea;Therapeutic Advances in Chronic Disease;2024-01